December 27, 2005 - 9:02 a.m.
Gilead to Repatriate Funds to the United States
Printer Friendly Version 
December 15, 2005 - 9:16 a.m.
Dr. George P. Shultz Resigns from Gilead Sciences Board of Directors
Printer Friendly Version 
December 13, 2005 - 9:16 a.m.
John W. Madigan Joins Gilead Sciences Board of Directors
Printer Friendly Version 
December 12, 2005 - 9:17 a.m.
Data Show Efficacy of Standard Dosing Regimen of AmBisome(R) is Similar to High Loading Dose for Patients with Invasive Fungal Infections
Printer Friendly Version 
December 06, 2005 - 4:32 p.m.
Gilead Launches an Educational Website on Advances in Combination Therapy For HIV
Printer Friendly Version 
December 02, 2005 - 4:32 p.m.
Gilead Sciences to Present at the NASDAQ 16th Investor Program on Thursday, December 8th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
November 28, 2005 - 4:32 p.m.
Gilead Sciences to Present at the Lazard Capital Markets Life Sciences Conference on Wednesday, November 30th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
November 17, 2005 - 4:32 p.m.
Preliminary 24-Week Data Evaluating the Impact of Switching from Twice-Daily Combivir(R) to Once-Daily Truvada(R) in Patients with HIV Presented at 10th European AIDS Conference
Printer Friendly Version 
November 16, 2005 - 1:33 a.m.
Gilead and Roche End Tamiflu(R) Dispute; Expanded Collaboration Includes Gilead Role in Oversight of Manufacturing and Commercialization
Printer Friendly Version 
November 14, 2005 - 4:17 p.m.
Five-Year Data Evaluating Long-Term Therapy with Hepsera(R) for Hepatitis B ''e'' Antigen-Negative Chronic Hepatitis B Presented at AASLD Annual Meeting
Printer Friendly Version 
November 11, 2005 - 4:32 p.m.
Gilead Sciences to Present at the Credit Suisse First Boston Healthcare Conference on Thursday, November 17th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
November 04, 2005 - 4:32 p.m.
Gilead Sciences to Present at the CIBC World Markets 16th Annual Healthcare Conference on Monday, November 7th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
October 18, 2005 - 4:03 p.m.
Gilead Sciences Announces Third Quarter 2005 Financial Results
Printer Friendly Version 
October 11, 2005 - 4:31 p.m.
Gilead Sciences to Release Third Quarter 2005 Financial Results on Tuesday, October 18, 2005; Conference Call and Webcast to Follow
Printer Friendly Version 
September 23, 2005 - 4:32 p.m.
Gilead Sciences to Present at the 2005 UBS Global Life Sciences Conference on Tuesday, September 27th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
September 02, 2005 - 5:09 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
August 29, 2005 - 5:02 p.m.
Gilead Reduces Prices for Viread(R) and Truvada(R) in the Developing World
Printer Friendly Version 
August 18, 2005 - 5:03 p.m.
Gilead Sciences' Board Member Amends Existing Rule 10b5-1 Stock Trading Plan
Printer Friendly Version 
August 15, 2005 - 4:02 p.m.
Gilead and Achillion Announce Initiation of Phase I Clinical Trial Evaluating GS 9132 for the Treatment of Hepatitis C
Printer Friendly Version 
August 09, 2005 - 4:17 p.m.
Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada(R) (Emtricitabine and Tenofovir Disoproxil Fumarate) and Sustiva(R) (Efavirenz)
Printer Friendly Version 
July 28, 2005 - 6:11 p.m.
Gilead Sciences Announces Management Promotions
Printer Friendly Version 
July 27, 2005 - 7:43 p.m.
John F. Cogan Joins Gilead Sciences Board of Directors
Printer Friendly Version 
July 22, 2005 - 3:24 p.m.
Gilead Sciences and Royalty Pharma Complete $525 Million Purchase from Emory University of Emtricitabine Royalty Interest
Printer Friendly Version 
July 19, 2005 - 4:05 p.m.
Gilead Sciences Announces Initiation of Phase III Clinical Program Evaluating Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B Virus
Printer Friendly Version 
July 19, 2005 - 4:02 p.m.
Gilead Sciences Announces Second Quarter 2005 Financial Results
Printer Friendly Version 
July 18, 2005 - 8:45 p.m.
Gilead Sciences and Royalty Pharma Announce $525 Million Agreement with Emory University to Purchase Royalty Interest for Emtricitabine
Printer Friendly Version 
July 12, 2005 - 4:32 p.m.
Gilead Sciences to Release Second Quarter 2005 Financial Results on Tuesday, July 19, 2005; Conference Call and Webcast to Follow
Printer Friendly Version 
June 29, 2005 - 5:01 p.m.
Data Evaluating Long-Term Therapy with Hepsera for Hepatitis B ''e'' Antigen-Negative Chronic Hepatitis B Published in the New England Journal of Medicine
Printer Friendly Version 
June 23, 2005 - 4:02 p.m.
Gilead Delivers Termination Notice to Roche for Tamiflu Development and Licensing Agreement
Printer Friendly Version 
June 21, 2005 - 4:31 p.m.
Gilead Announces Initiation of Phase I/II Clinical Trial Evaluating HIV Integrase Inhibitor GS 9137
Printer Friendly Version 
June 10, 2005 - 4:31 p.m.
Gilead Sciences to Present at the Goldman Sachs 26th Annual Global Healthcare Conference on Wednesday, June 15th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
May 27, 2005 - 4:32 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
May 13, 2005 - 4:32 p.m.
Gilead Sciences to Present at the Banc of America Securities Health Care Conference 2005 on Tuesday, May 17th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
April 29, 2005 - 4:32 p.m.
Gilead Sciences' Board Member Establishes Rule 10b5-1 Stock Trading Plan
Printer Friendly Version 
April 26, 2005 - 4:07 p.m.
Gilead Provides Update on Development of Fixed-Dose Regimen of Truvada -emtricitabine and tenofovir disoproxil fumarate- and Sustiva -efavirenz-
Printer Friendly Version 
April 25, 2005 - 1:19 p.m.
Gilead Sciences and Aspen Pharmacare Sign Letter of Intent to Establish Non-Exclusive Licensing and Distribution Agreement for Antiretrovirals Truvada and Viread in Developing World Countries
Printer Friendly Version 
April 19, 2005 - 4:02 p.m.
Gilead Sciences Announces First Quarter 2005 Financial Results
Printer Friendly Version 
April 08, 2005 - 8:32 a.m.
Gilead Sciences to Release First Quarter 2005 Financial Results on Tuesday, April 19, 2005; Conference Call and Webcast to Follow
Printer Friendly Version 
April 04, 2005 - 4:32 p.m.
Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period for the Japan Tobacco License for JTK-303
Printer Friendly Version 
March 28, 2005 - 4:31 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
March 22, 2005 - 2:02 a.m.
Gilead and Japan Tobacco Sign Licensing Agreement for Novel HIV Integrase Inhibitor
Printer Friendly Version 
March 16, 2005 - 8:33 a.m.
Gilead Expands Global Access Program for HIV Therapies to Include Additional Countries in the Caribbean and Latin America; Bahamas Manufacturing Plant Established
Printer Friendly Version 
March 11, 2005 - 4:31 p.m.
Gilead Sciences to Present at the SG Cowen & Co. 25th Annual Health Care Conference on Tuesday, March 15th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
February 28, 2005 - 8:31 a.m.
48-Week Data Comparing Viread Versus Abacavir as Replacement for Thymidine Analogue in Lipoatraphic HIV Patients Presented at the 12th Conference on Retroviruses and Opportunistic Infections
Printer Friendly Version 
February 23, 2005 - 10:41 a.m.
European Commission Approves Truvada, a Once-a-Day Tablet Containing Gilead Sciences' Anti-HIV Drugs Emtriva and Viread
Printer Friendly Version 
February 04, 2005 - 4:32 p.m.
Gilead Sciences to Present at the Merrill Lynch Global Pharmaceutical, Medical Device, and Biotechnology Conference on Tuesday, February 8th
Printer Friendly Version 
February 03, 2005 - 8:32 a.m.
Gilead Announces Preliminary 48-Week Data From Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Sustiva in Patients With HIV
Printer Friendly Version 
January 27, 2005 - 4:02 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2004 Financial Results
Printer Friendly Version 
January 21, 2005 - 4:31 p.m.
Gilead Sciences to Release Fourth Quarter and Year End 2004 Financial Results on Thursday, January 27, 2005; Conference Call and Webcast to Follow
Printer Friendly Version 
January 05, 2005 - 4:32 p.m.
Gilead Sciences to Present at the 23rd Annual JPMorgan Healthcare Conference on Monday, January 10th; Webcast Available Through Gilead Corporate Website
Printer Friendly Version 
NASDAQ (US Dollar)
$72.11
 Stock is Down 0.23 (0.32%)
Data as of 08/18/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote